The Blood and Marrow Transplant Program at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital.

For questions, call (404)-255-1930

How to Refer a Patient

Physician Bios

How to Donate Blood and Platelets

New Patient Forms

Privacy Practice

Map & Directions

Employment Opportunities

Please e-mail your resume or send any questions to the following e-mail address: You may also call Marianne Silverboard at 404 255-1938 ext. 1104.

Click to help

Updated Allogeneic Transplant Survival Outcome Data Over Performing 2009 - 2017

The NSH BMT Program is the only adult BMT Program in Georgia, to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic transplants for the last 9 consecutive reporting cycles (2009-2017)1,2. Survival outcome achievements include:

  • In the top 20% for volume for allogeneic transplants and largest allogeneic center in Georgia
  • 9th consecutive reporting cycle in ‘Over Performing’ category
  • 1 of 2 centers nationally who have over-performed for transplants performed over a decade (2003 – 2015)

We believe our programs’ commitment to quality has consistently increased patient survival rates and lower treatment-related mortality rates. There were 174 adult and pediatric transplant centers included in the analysis.

Please click Survival and for additional information.

1. Reported outcome data from This survival information includes only patients who received their first allogeneic transplant between January 1, 2013 and December 31, 2015 using unrelated or related donors, and who had reported follow-up.
2. Final 2017 Transplant Center Specific Survival Report, December, 2017 
the last 9 consecutive reporting cycles

Congratulations to the NSH-BMT Program Only Transplant Program in Georgia Named as a Core Center for Grant Period 2017- 2023

NSH-BMT program achieved BMT CTN Core Center Grant renewal funding for years 2017 – 2023. Past performance, current application, and PI leadership contributed to the grant renewal. NSH-BMT applied as a consortium with University of Miami and Levine Cancer Institute. The National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) provide BMT CTN research grant funding.

Achieving this award is a validation of the efforts of each person in the program, the support of the administration, and leadership of the BMTGA physicians. For further information, please read Press Release.

NSH BMT/Leukemia Program Presents Groundbreaking Study the 2017 American Society of Hematology (ASH) Conference

Dr. Scott Solomon presented a groundbreaking study: “Selecting the Best Donor for T-Cell-Replete Haploidentical Transplantation: Importance of HLA Disparity, NK Alloreactivity, and Other Clinical Variables”, at the 2017 ASH conference, held in Atlanta, Georgia. The study identified new donor selection criteria, including HLA DP typing and KIR genotyping, tests which are not currently being performed routinely for donor selection. These criteria are important factors in selecting the best haploidentical donor. The study also showed that when these two criteria were met, patient survival rates increased.

This study would not have occurred without the generous support of the Northside Hospital Foundation’s Cancer Research Fund. Through donations, this fund provides Northside Hospital Cancer Institute investigators the ability to develop cutting-edge research for cancer treatment, prevention, early detection, survivorship, and more.

NSH-BMT/Leukemia Team Participates in the 2017 Light The Night Fundraising Walk

For the first time in nineteen years, the Leukemia and Lymphoma Society’s (LLS) Light The Night walk was held at Piedmont Park. On October 7, 2017, survivors, patients, families and practitioners gathered together to celebrate, honor and remember those touched by cancer. The walk itself is a showing of emotional support for our patients during their cancer journey. The proceeds from this fundraising event also provide our patients with financial and emotional support during their cancer journey. 

The BMT/Leukemia team was led by the inpatient team. Over 1.2 million dollars were raised, ranking tenth in the USA for funding raising dollars.  We thank all those who participated and supported the 2017 LLS Light The Night walk.

BMT Program at Northside Renews its Status as a Core Clinical Center for the Blood and Marrow Transplant Clinical Trials Network

Northside Hospital Cancer Institute's Blood and Marrow Transplant (BMT) Program is pleased and honored to learn that it is one of twenty BMT Programs and Program Consortia to be selected as a Core Clinical Center for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

Click here to read more on this story and others in the lastest BMT Newsletter

Exceeding Expectations
Immunotherapy Research Leads to Better Outcomes for Leukemia and BMT Patients

Please read Drs. Asad Bashey and Lawerence Morris’ comments on how immunotherapy research has positively impacted survival outcomes for BMT and leukemia patients. 

Congratulations to Our Atlanta Top Doctors

The Blood and Marrow Transplant Group of Georgia physicians, Asad Bashey, H. Kent Holland, Lawrence Morris, and Scott Solomon, have been voted by their peers as Atlanta Top Doctors. Our Physician Team provides outstanding patient and referring physician customer service which has resulted in exceptional survival outcomes and excellent patient /referring physician satisfaction.

The Top Doctor nominating process, conducted by Castle Connolly, a healthcare research and information company founded in 1991. Castle Connolly identifies the top doctors in America and provides consumers with detailed information about their education, training, and special expertise. Its online nominations process, , is open to all U.S. licensed physicians. Doctors do not and cannot pay to be selected and profiled as Castle Connolly Top Doctors.

Please visit the Atlanta Magazine Top Doctor edition at

Neal Brasfield, Unrelated Allogeneic Transplant Recipient, Meets His Donor at the Blood & Marrow Transplant Reunion

To view additional BMT reunion photos, please go to Survivorship

Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Phase 1 Clinical Research Trial Open for Enrollment

Click Here for Details

Advances in Immunotherapy for Cancer: Novel Clinical Research Trial Open at Northside Hospital’s Blood and Marrow and Transplant Program

Click Here for Details

NSH - BMT’s Clinical Program, Collection Facility and Hematopoietic Stem Cell Processing Laboratory Receives a Perfect FACT (Foundation for Accreditation of Cellular Therapy) Inspection Score

In November 2015, the NSH - BMT Clinical Program, Collection Facility (Atlanta Blood Services) and the Hematopoietic Stem Cell Laboratory underwent the required three year FACT inspection. Each area was praised for their commitment to a culture of quality, patient safety and continuously striving for high patient satisfaction. We believe our continuous process improvement, open communication and focusing on improving patient care has resulted in superior survival outcomes. NSH-BMT’s clinical program has received perfect FACT inspection scores during their 2003, 2006, 2009, 2012, and 2015 inspections.


Ashlee Holbein, RN, FACT/QI Coordinator and Melissa Horowitz, RN, Supervisor of Program Quality & Clinical Coordinators

BMT Program Quality External Audits: FACT

Consecutive Inspections Resulted in ZERO Clinical Deficiencies

Updated 2017 Referral Guidelines: Recommended Timing For Transplant Consultation

Disease stage at the time of transplant can have a significant impact on patient survival [1] appropriate planning and early donor identification are critical for optimal outcomes.

The 2017 referral timing guidelines were developed jointly by the National Marrow Donor Program® (NMDP) /Be The Match® and the American Society for Blood and Marrow Transplantation (ASBMT) and are based on current clinical practice, medical literature, and evidence-based reviews. [1,2]

The guidelines highlight disease categories that include patients at risk for disease progression, who should be referred for consultation for autologous or allogeneic HCT.[3]

If you have questions as to when to refer a patient for initial transplant consult, please call 404-255-1930 and ask to speak to one of our transplant physicians.

  1. Lee, SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13): 4576-4583. Access
  2. Pidala J, Lee SJ, Ahn KW, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014:124(16):2596-2606. Access
  3. NMDP/Be The Match & ASBMT Recommended Timing for Transplant Consultation, 2017. Download (PDF) 

Post-Transplant New Mobile App is Now Available

To help physicians with the reference materials they need to care for transplant patients, BeTheMatch has developed a free Transplant Guideline mobile app, available through the Apple© and AndroidTM app stores. For more information please visit


Post- Blood and Marrow Transplant Immunization Schedule- What You Need to Know

After blood and marrow transplant, patients will need to be re-immunized with all childhood vaccinations due to their new immune systems being immature and vulnerable to diseases/infections. It is recommended that post-transplant patients begin their vaccination schedule six months after transplant unless clinically contraindicated. The Centers for Disease Control (CDC), recommends the following:

  • Inactivated influenza vaccine should be administered beginning at least 6 months after HCT and annually thereafter for the life of the patient.
  • Sequential administration of 3 doses of pneumococcal conjugate vaccine is recommended, beginning 3-6 months after the transplant, followed by a dose of PPSV.
  • A 3-dose regimen of Hib vaccine should be administered beginning 6 months after transplant; at least 1 month should separate the doses.
  • MMR vaccine should be administered 24 months after transplant if the HCT recipient is immunocompetent.
  • If a decision is made to vaccinate with varicella vaccine, the vaccine should be administered a minimum of 24 months after transplantation if the HCT recipient is presumed to be immunocompetent.
Please click here to view the NSH-BMT post-transplant vaccination schedule recommended for both autologous and allogeneic transplant recipients. For more specific information, see Tomblyn M, Chiller T, Einsele H, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective [1.9MB, 96 pages]. Biol Blood Marrow Transplant 15:1143-1238;2009 or visit

Atlanta Blood Services, Program Collection Facility, Celebrates Donor James Arnett’s 250th Platelet Donation

James Arnett recently donated his platelets for the 250th time. To celebrate this occasion, Carrie Cox, Executive Director, Atlanta Blood Services, dedicated one of its platelet collection devices in James’ honor. For the last five years, James has donated platelets on an average of 24 times per year. His first donation was May 22, 2002, after his son’s teacher was diagnosed with cancer. All platelet donations are kept locally and used for leukemia, cancer patients, and neonatal intensive care unit infants.
To read more about James’ platelet donations, please click Neighbor News 

Platelet Donation Video - Atlanta Blood Services

Hesitant about donating platelets? Our wonderful platelet hero Dave takes the guesswork out of donating! The process is very similar to donating whole blood, and with your donation you are giving the gift of life to an active blood cancer or blood disorder patient right here in Atlanta!

Call 404-459-8744 and schedule your appointment to save lives today!

Click here to view video


The Blood and Marrow Transplant Program at Northside Hospital (NSH-BMT) provides the best of both worlds — clinical excellence and compassionate care. Committed to being the premier program in the Southeast, we provide outstanding state-of-the-art care for patients with leukemia and for those patients undergoing blood marrow and stem cell transplantation.